CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017

ACC 2017 Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.

Educational information

The FOURIER trial was presented during Late-Breaking Clinical Trial Session 1 (March 17), ACC 2017, Washington DC, USA

Recorded at ACC 2017, Washington DC, USA

Disclosures

Dr. Marc S. Sabatine, Brigham and Women's Hospital, Boston, USA (Chairman of the Thrombolysis in Myocardial Infarction (TIMI) Study Group; Lead Author FOURIER study)

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.